AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31

Akebia Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$0.68+0.01 (+1.51%)

Close on Oct 19, 2026

Market cap: $183.36M
P/E (TTM): –
Dividend yield: –

Akebia Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31
Revenue	236	160	195	292	212	295	335	208	181	1.54	0	0	–	–
Cost of Revenue	39	63	74	86	151	296	145	7.77	–	–	–	–	–	–
Gross Profit	197	97	120	207	61	-1.83	190	200	–	–	–	–	–	–
Research & Development	62	38	63	130	148	218	323	291	231	116	43	23	8.90	5.63
Selling, General & Admin	107	107	100	139	174	154	149	87	27	22	–	–	–	–
General & Administrative	–	–	–	–	–	–	–	–	27	22	18	15	7.03	2.89
Operating Expenses	173	147	167	288	325	376	476	378	258	138	62	38	16	8.52
Operating Income	23	-50	-46	-81	-265	-378	-286	-178	-77	-136	-62	-38	-16	-8.52
Interest & Investment Income	–	–	–	–	–	–	–	–	–	0.90	0.51	0.21	–	–
Other Non-Operating Income	0.06	0.09	0.89	3.15	2.41	1.86	-0.79	0.08	0.20	-0.19	0.29	0.70	–	–
Merger & Restructuring Charges	0	0.06	0.18	16	0	0	–	–	–	–	–	–	–	–
Asset Impairment Charges	0	0	0	0	0	0	0	0	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	0.17	0	0	–	0	0	-2.05	0	–	-0.31	–	–	–	–
Pretax Income	-3.72	-69	-52	-94	-282	-385	-286	-172	-74	-136	–	–	–	–
Income Tax Expense	1.62	0	0	0	0	0	-6.63	-28	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	–	–	–	-94	-282	-385	-280	-144	-74	–	–	–	–	–
Net Income	-5.35	-69	-52	-94	-282	-385	-280	-144	-74	-136	-61	-37	-13	-8.20
Net Income to Common	–	–	–	–	–	–	–	–	–	-136	-61	-124	-69	-12
EPS (Basic)(per share)	-0.02	-0.33	-0.28	-0.52	-1.70	-2.78	-2.36	-2.47	-1.69	-3.60	-2.29	-8.04	-126.94	-27.82
EPS (Diluted)(per share)	-0.02	-0.33	-0.28	-0.52	-1.70	-2.78	-2.36	-2.47	-1.69	-3.60	-2.29	-8.04	-126.94	-27.82
Shares Outstanding (Basic, Weighted)(shares)	257	211	187	183	166	138	118	58	44	38	26	15	0.54	0.41
Shares Outstanding (Diluted, Weighted)(shares)	257	211	187	183	166	138	118	58	44	38	26	15	0.54	0.41
EBITDA	–	–	–	-79	-263	-376	-284	-177	-76	-136	-61	-38	–	–
Net Interest Income	–	–	–	–	–	–	–	–	–	–	0.51	0.21	-0.70	-1.64

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 79.6%
Operating margin: -6.9%
Net margin: -13.5%
Return on equity, FY2025: 64.5%

Financial strength

Current ratio: 1.43
Debt to equity: 1.98
Debt to assets: 14.2%
Cash to current liabilities: 96.7%

Valuation

P/E ratio: –
Price to sales: 0.84
Price to book: 7.33
Dividend yield: –